FY2025 EPS Forecast for Organigram Global Cut by Analyst

Key Points

• Alliance Global Partners has reduced its forecast for Organigram's FY2025 earnings per share from $0.09 to $0.07, indicating a downward revision in expectations.
• Organigram's recent quarterly results reported an EPS of ($0.03), missing the consensus estimate of ($0.01) by $0.02, with revenues falling short of expectations at $50.49 million.
• Despite the downturn in earnings projections, significant changes in institutional investor positions suggest continued interest, with 34.63% of Organigram's stock held by such investors.

Organigram Global Inc. (NASDAQ:OGI - Free Report) - Research analysts at Alliance Global Partners decreased their FY2025 earnings per share estimates for Organigram Global in a report issued on Wednesday, August 13th. Alliance Global Partners analyst A. Grey now anticipates that the company will post earnings per share of $0.07 for the year, down from their previous forecast of $0.09. The consensus estimate for Organigram Global's current full-year earnings is ($0.19) per share. Alliance Global Partners also issued estimates for Organigram Global's Q1 2026 earnings at ($0.02) EPS.

Organigram Global (NASDAQ:OGI - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.02). Organigram Global had a net margin of 2.86% and a negative return on equity of 8.19%. The company had revenue of $50.49 million during the quarter, compared to analyst estimates of $68.04 million.

Separately, Wall Street Zen lowered Organigram Global from a "hold" rating to a "sell" rating in a research report on Saturday.

Organigram Global Stock Performance

Shares of NASDAQ:OGI traded down $0.02 during midday trading on Friday, reaching $1.50. The company had a trading volume of 593,540 shares, compared to its average volume of 728,178. Organigram Global has a 1-year low of $0.85 and a 1-year high of $2.0550. The firm has a market cap of $201.08 million, a price-to-earnings ratio of 30.01 and a beta of 1.45. The company has a fifty day simple moving average of $1.43 and a two-hundred day simple moving average of $1.27.

Institutional Investors Weigh In On Organigram Global

Several hedge funds have recently bought and sold shares of the business. Tidal Investments LLC lifted its stake in Organigram Global by 4.9% in the 2nd quarter. Tidal Investments LLC now owns 2,646,879 shares of the company's stock worth $3,573,000 after acquiring an additional 124,356 shares in the last quarter. Cidel Asset Management Inc. lifted its stake in Organigram Global by 112.3% in the 2nd quarter. Cidel Asset Management Inc. now owns 37,103 shares of the company's stock worth $50,000 after acquiring an additional 19,627 shares in the last quarter. Vontobel Holding Ltd. lifted its stake in Organigram Global by 140.5% in the 2nd quarter. Vontobel Holding Ltd. now owns 69,753 shares of the company's stock worth $94,000 after acquiring an additional 40,753 shares in the last quarter. Clear Harbor Asset Management LLC purchased a new stake in Organigram Global in the 2nd quarter worth about $54,000. Finally, Baader Bank Aktiengesellschaft purchased a new stake in Organigram Global in the 2nd quarter worth about $338,000. 34.63% of the stock is owned by hedge funds and other institutional investors.

About Organigram Global

Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.